The China Cancer Vaccines Market was valued at $2237.1 Million in 2024 and projected to reach to $3359.4 Million by 2029, representing a compound annual growth rate of 5.2%. China's cancer vaccines market is poised for sustained expansion driven by rising cancer incidence, government healthcare initiatives, and increased R&D investments in immunotherapy.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China's cancer vaccines market is valued at $2,237.1 million in 2024, with a projected CAGR of 5.2% through 2029, reaching $3,359.4 million by forecast end.
China's healthcare infrastructure modernization and government backing for immunotherapy development are accelerating cancer vaccine adoption and clinical research initiatives across the nation.
Increasing cancer prevalence rates in China are driving demand for innovative therapeutic solutions, positioning cancer vaccines as a critical component of the oncology treatment landscape.
China's growing investment in oncology therapeutics reflects strategic prioritization of cancer care, creating opportunities for vaccine developers and biopharmaceutical companies in the region.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | OTHER VACCINE TECHNOLOGIES (Technology) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 5.4% from 2024 to 2029 |
| Largest Segment | PREVENTIVE VACCINES (Type) |
| Market Size Base Year (Billions) | ~USD 9.85 (2024) |
| Revenue Forecast (Billions) | ~USD 15 (2029) |
| Segments Covered | Type, Technology, Route Of Administration, Indication, End User |
5 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2032 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS | 1407.5 | 1861.3 | 1890.8 | 1956.7 | 2031.8 | 2125.5 | 2227.8 | 2844.7 | 5.2 |
| SPECIALTY CLINICS & CENTERS | 258.6 | 341.4 | 346.3 | 357.8 | 371 | 387.5 | 405.5 | 514.7 | 5.1 |
| TOTAL | 1666 | 2202.8 | 2237.1 | 2314.5 | 2402.8 | 2513 | 2633.4 | 3359.4 | 5.2 |
China's cancer vaccines market was valued at $2,237.1 million in 2024 and is projected to grow to $3,359.4 million by 2029.
China's cancer vaccines market is expected to grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2029.
Key drivers include rising cancer incidence rates, government support for immunotherapy, healthcare infrastructure modernization, and increased clinical trial activity in China.
China represents a significant portion of the Asia Pacific market, with a 5.2% CAGR compared to the global CAGR of 5.4%, reflecting strong regional growth potential.
China benefits from advanced manufacturing capabilities, cost-effective production models, a large patient population, and growing expertise in personalized medicine and immunotherapy.
The research study involved the wide use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global cancer vaccines market. Extensive interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size estimated through secondary research (top down and bottom-up) followed by data triangulation with inputs from industry experts to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the technical, market-oriented, and commercial study of the cancer vaccines market. The secondary sources used for this study include National Cancer Institute (NCI), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), National Institute of Allergy and Infectious Diseases (NIAID), International Society for Vaccines (ISV), United Nations Children’s Fund (UNICEF), GAVI, Pan American Health Organization (PAHO), Medical Research Council (MRC), World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations among others. These secondary sources were also used to obtain major information about key market players, and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analysed to arrive at the market size of the global cancer vaccines market, which was further validated through primary research.
Extensive primary research was conducted after acquiring basic knowledge about the global cancer vaccines market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biopharmaceutical industries from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. The primary interviews were conducted across six major regions, including the North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Approximately 65% and 35% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cancer vaccines market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Cancer vaccines are biopharmaceutical products designed to prevent or treat cancer by stimulating the body's immune system to recognize and attack cancer cells. Cancer vaccines are categorized as preventive (e.g., HPV and hepatitis B vaccines to prevent cancer-causing infections) or therapeutic, which aim to treat existing cancers. Therapeutic vaccines may use tumor-associated antigens, personalized neoantigens, or immune-stimulating components like adjuvants to enhance efficacy. In the report we have considered FDA and other regional regulatory body approved products as cancer vaccines.
Full forecast, segment splits, and company analysis for all Cancer Vaccines Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report